Loading...
Loading...
Spherix
Incorporated
SPEX and Fullife Healthcare Pvt. Ltd. – an
innovation-driven company focused on bringing unique healthcare solutions to
India – today announced the signing of a supply and license agreement for the
use of D-tagatose in nutraceutical products in India.
Under the terms of the agreement, Spherix has granted Fullife an exclusive,
royalty-bearing license in India for use of Spherix's clinical data and
proprietary know-how to support marketing and dosing of the D-tagatose that
Spherix will also be supplying. The D-tagatose will be used in food or
cosmetic products that may provide health benefits in return for a fixed
royalty on gross sales. Spherix will provide bulk D-Tagatose to Fullife and
Fullife will be responsible for all testing and development of products
containing D-Tagatose for sale in India. Financial terms of the agreement were
not disclosed.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in